Načítá se...
Risk of de novo hepatocellular carcinoma following use of direct acting antiviral medications for treatment of chronic hepatitis C
Direct-acting antivirals (DAA) are now the mainstay of treatment for patients with chronic hepatitis C virus (HCV); however, there is some controversy over whether use of DAAs for HCV, as compared with interferon (IFN)-based regimens, leads to an increased risk of hepatocellular carcinoma (HCC) deve...
Uloženo v:
| Vydáno v: | Cancer Prev Res (Phila) |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6893130/ https://ncbi.nlm.nih.gov/pubmed/31451519 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1940-6207.CAPR-19-0162 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|